1-3 of 3
Hana Filkova
Close
Sort by
Journal Articles

Prognostic Significance of Morphological Evaluation of Tumor Cells in Multiple Myeloma.

Mohammed Al-sahmani, MD, Irena Trnavska, Monika Antosova, Libuse Antosova, Jarmila Kissova, MD, Hana Filkova, M.Sc., Jan Smetana, M.Sc., Zdenek Adam, MD, Prof., Ludek Pour, MD, Marta Krejci, MD, Lenka Zahradova, MD, Alena Bulikova, MD, Miroslav Penka, Prof., Petr Kuglik, Ass., Prof., Roman Hajek, MD, Prof.
Journal: Blood
Blood (2009) 114 (22): 4889.
https://doi.org/10.1182/blood.V114.22.4889.4889
Published: 2009
Journal Articles

Gain(1)(q21) Defines Group of Newly Diagnosed Multiple Myeloma Patients with Poor Prognosis.

Pavel Nemec, M.Sc., Henrieta Greslikova, D.Sc., Romana Zaoralova, M.Sc., Jan Smetana, M.Sc., Hana Filkova, M.Sc., Elena Dementyeva, MD, Renata Kupska, Kristina Berankova, B.Sc., Aneta Mikulasova, B.Sc., Ludek Pour, MD, Lenka Zahradova, MD, Petr Kuglik, Roman Hajek, MD,
Journal: Blood
Blood (2009) 114 (22): 2820.
https://doi.org/10.1182/blood.V114.22.2820.2820
Published: 2009
Journal Articles

Newly Diagnosed Multiple Myeloma Patients with 1q21 Amplification Treated by Autologous Stem Cell Transplantation Have Shorter Progression-Free Survival Interval.

Pavel Nemec, Henrieta Greslikova, RNDr., Petr Kuglik, doc., RNDr., CSc., Hana Filkova, Romana Zaoralova, Vladimira Vranova, RNDr., Ph.D., Jana Smejkalova, Ph.D., Petra Vidlakova, Alexandra Oltova, RNDr., Roman Hajek, MUDr. CSc.
Journal: Blood
Blood (2007) 110 (11): 4758.
https://doi.org/10.1182/blood.V110.11.4758.4758
Published: 2007